Briumvi® - Real World Experience Study in Europe (BRILL-EU Study)

• Research type

  Research Study

• Full title

  Non-interventional, prospective, multicenter, European study to evaluate treatment satisfaction, treatment preference, quality of life, and tolerability under treatment with Briumvi® for relapsing forms of multiple sclerosis (RMS) with active disease in daily clinical practice

• IRAS ID

  356096

• Contact name

  Andreas Schmitt

• Contact email

  a.schmitt@neuraxpharm.de

• Sponsor organisation

  Neuraxpharm Pharmaceuticals, S.L.

• Duration of Study in the UK

  4 years, 0 months, 0 days

• Research summary

  The aim of this non-interventional study (NIS) is to document the use of Briumvi® in routine clinical practice over a period of approx. 2 years in Spain, Italy, the UK, and France. The focus of the data collection is on treatment satisfaction, treatment preference, health-related quality of life, disability progression and tolerability in a typical MS patient population under real-life conditions.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  25/EM/0150

• Date of REC Opinion

  23 Jul 2025

• REC opinion

  Further Information Favourable Opinion